Format

Send to

Choose Destination
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Author information

1
University of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: aribas@mednet.ucla.edu.
2
University Hospital of Zurich, Zurich, Switzerland.
3
Roswell Park Cancer Institute, Buffalo, NY, USA.
4
The West Clinic, Memphis, TN, USA.
5
University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
6
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
7
Fox Chase Cancer Center, Philadelphia, PA, USA.
8
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain.
9
Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, LaTrobe University, Heidelberg, VIC, Australia.
10
Hopitaux Universitaires de Genève, Geneva, Switzerland.
11
University of Pittsburgh Cancer Institute and Hillman UPMC Cancer Center, Pittsburgh, PA, USA.
12
The University of Chicago School of Medicine, Chicago, IL, USA.
13
Amgen Inc., Thousand Oaks, CA, USA.
14
Amgen Inc., South San Francisco, CA, USA.
15
Merck & Co., Inc., Kenilworth, NJ, USA.
16
Dana-Farber Cancer Institute, Boston, MA, USA.
17
Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

Abstract

Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8+ T cells, elevated PD-L1 protein expression, as well as IFN-γ gene expression on several cell subsets in tumors after talimogene laherparepvec treatment. Response to combination therapy did not appear to be associated with baseline CD8+ T cell infiltration or baseline IFN-γ signature. These findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment. VIDEO ABSTRACT.

KEYWORDS:

T lymphocytes; anti-PD-1; biomarkers; cytotixic; interferon gamma; melanoma; oncolytic immunotherapy; oncolytic viruses; pembrolizumab; talimogene laherparepvec; tumor; tumor microenvironment

PMID:
28886381
DOI:
10.1016/j.cell.2017.08.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center